4.8 Article

Genetic impairment of succinate metabolism disrupts bioenergetic sensing in adrenal neuroendocrine cancer

Journal

CELL REPORTS
Volume 40, Issue 7, Pages -

Publisher

CELL PRESS
DOI: 10.1016/j.celrep.2022.111218

Keywords

-

Categories

Funding

  1. SDHB Para/Pheo Coalition
  2. Neuroendocrine Tumor Research Foundation
  3. NIH [MH116896, MH126948]
  4. Robert E Reed Gastrointestinal Oncology Research Foundation
  5. American Cancer Society Institutional Research Grant Junior Faculty Development Award
  6. Intramural Research Program of the Eunice Kennedy Shriver NICHD, NIH
  7. Gatorade Trust
  8. University of Florida, Department of Medicine
  9. Eurostars grant (CYST -ARREST)
  10. National Cancer Institute Cancer Center
  11. NCI SPORE [P50 CA127297]
  12. (Eppley Institute for Research in Cancer and Allied Disease) [1145265]
  13. National Health and Medical Research Council (NHMRC)
  14. Victorian Governments Operational Infrastructure Support Program
  15. UAB Diabetes Research Center [NIH P30 DK-079626]

Ask authors/readers for more resources

Metabolic dysfunction mutations can lead to cancer. Loss of SDHB triggers a signaling cascade that disrupts energy sensing and promotes cancer progression.
Metabolic dysfunction mutations can impair energy sensing and cause cancer. Loss of function of the mitochondrial tricarboxylic acid (TCA) cycle enzyme subunit succinate dehydrogenase B (SDHB) results in various forms of cancer typified by pheochromocytoma (PC). Here we delineate a signaling cascade where the loss of SDHB induces the Warburg effect, triggers dysregulation of [Ca2+](i), and aberrantly activates calpain and protein kinase Cdk5, through conversion of its cofactor from p35 to p25. Consequently, aberrant Cdk5 initiates a phospho-signaling cascade where GSK3 inhibition inactivates energy sensing by AMP kinase through dephosphorylation of the AMP kinase gamma subunit, PRKAG2. Overexpression of p25-GFP in mouse adrenal chromaffin cells also elicits this phosphorylation signaling and causes PC. A potent Cdk5 inhibitor, MRT3-007, reverses this phospho-cascade, invoking a senescence-like phenotype. This therapeutic approach halted tumor progression in vivo. Thus, we reveal an important mechanistic feature of metabolic sensing and demonstrate that its dysregulation underlies tumor progression in PC and likely other cancers.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available